HC Surgical Specialists Limited Announces Strategic Acquisition of 51% Stake in Chirurgia Pte. Ltd.
Key Points of the Announcement
- Acquisition Details: HC Surgical Specialists Limited (“HC Surgical” or the “Company”) has acquired a majority 51% equity interest in Chirurgia Pte. Ltd. (“Chirurgia”) for a total cash consideration of S\$1,228,000.
- Strategic Fit: Chirurgia operates “LS Lee Surgery” at Mount Elizabeth Novena Hospital, specializing in minimally invasive surgery and treatment of gallbladder diseases. This complements HC Surgical’s existing core strengths in general surgery and endoscopy, offering significant business synergy.
- Financial Performance of Chirurgia: For the 12 months ended 30 June 2025, Chirurgia recorded an unaudited net profit before tax of approximately S\$495,000. The company’s net tangible asset value and net asset value as at 30 June 2025 stood at S\$1,241,000.
- Funding and Valuation: The acquisition was financed fully via internal resources. The purchase price was determined on a willing-buyer, willing-seller basis, considering Chirurgia’s future growth potential, synergistic benefits for the Group, and the expertise and industry reputation of Dr. Lee Lip Seng, the vendor and founder of Chirurgia.
- Corporate Profile: HC Surgical is a leading medical services group in Singapore, operating 19 clinics specializing in endoscopic and general surgery services, notably in colorectal procedures.
Important Information for Shareholders
- Potential Impact on Share Price: This acquisition could be price-sensitive as it strengthens HC Surgical’s position in the minimally invasive surgery segment and immediately brings in a profitable business. With Chirurgia generating S\$495,000 in profit before tax (unaudited, 12 months ending June 2025), this deal is likely to be earnings-accretive for the Group.
- Synergistic Growth: The addition of Chirurgia’s expertise and services is expected to drive cross-referrals, operational efficiencies, and broaden HC Surgical’s service offerings, potentially enhancing long-term shareholder value.
- Reputation and Expertise: The involvement of Dr. Lee Lip Seng, a reputed surgeon, is a valuable asset that may accelerate Chirurgia’s growth and integration into the Group.
- No Open Market Value: There is no open market value available for Chirurgia, so the valuation was negotiated directly between buyer and seller based on future potential and current performance.
- Regulatory Disclosure: This transaction was announced in accordance with Rule 706A of the Catalist Rules, ensuring transparency and timely disclosure to investors.
Further Details
- The transaction was completed on 6 April 2026, with full payment made in cash.
- Shareholders seeking more information are advised to refer to the Company’s detailed announcement dated 6 April 2026 for full transaction terms.
- This development aligns with HC Surgical’s ongoing strategy to expand its service range and consolidate its market position in Singapore’s specialist healthcare sector.
About HC Surgical Specialists Limited
Incorporated on 1 September 2015 and listed on the SGX Catalist board on 3 November 2016, HC Surgical and its subsidiaries form a specialized medical group with a focus on endoscopic, colorectal, and general surgical procedures. The Group operates a network of 19 clinics throughout Singapore, providing accessible and specialized care.
Conclusion
Investor Takeaway: The acquisition of Chirurgia Pte. Ltd. marks a strategic and potentially earnings-enhancing move for HC Surgical Specialists Limited. The transaction strengthens the Group’s operational capabilities and service portfolio, while the immediate profit contribution and synergistic potential may be positive catalysts for the share price. Shareholders are encouraged to monitor future announcements for integration updates and financial results.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisors before making any investment decisions. The Singapore Exchange and the Company’s sponsor have not approved the contents of this article.
HC Surgical Specialists Limited 收购 Chirurgia Pte. Ltd. 51% 股权 —— 投资者详细解读
公告要点
- 收购详情：HC Surgical Specialists Limited（“HC Surgical”或“公司”）以1,228,000新元现金总价收购了Chirurgia Pte. Ltd.（“Chirurgia”）51%的股权。
- 战略协同：Chirurgia在伊丽莎白诺维娜医院运营“LS Lee Surgery”诊所，专注于微创手术及胆囊疾病治疗，与HC Surgical现有的普通外科和内镜专长高度互补，具备显著协同效应。
- Chirurgia 财务表现：截至2025年6月30日的12个月，Chirurgia未经审计的税前净利润约为495,000新元。截至2025年6月30日，Chirurgia的有形净资产和净资产均为1,241,000新元。
- 资金及估值：本次收购全额以公司内部资源支付。价格由买卖双方基于Chirurgia未来潜力、协同价值及创办人李立成医生的专业声誉协商达成。
- 公司简介：HC Surgical是新加坡领先的医疗服务集团，在全国共运营19家诊所，专注于内镜及普通外科服务，尤其以结直肠手术见长。
股东须知要点
- 对股价的潜在影响：本次收购增强了HC Surgical在微创手术领域的实力，并带来即期盈利贡献，预计对集团盈利有正面推动，具有潜在股价敏感性。
- 协同增长动能：Chirurgia的加入有望带动交叉转诊、提升运营效率、丰富服务产品线，为股东创造长期价值。
- 专家与声誉：创办人李立成医生作为业界专家，其加入有助于Chirurgia快速发展并与集团整合。
- 无公开市场估值：Chirurgia暂无公开市场估值，收购价格由双方基于未来潜力与当前业绩协商。
- 合规信息披露：本次交易依据Catalist规则706A公告，确保投资者及时获得透明信息。
更多细节
- 交易于2026年4月6日完成，全部以现金支付。
- 欲了解详细条款，请查阅公司2026年4月6日发布的收购公告。
- 本次收购符合HC Surgical持续扩展服务领域、巩固新加坡专科医疗市场地位的战略。
关于 HC Surgical Specialists Limited
HC Surgical成立于2015年9月1日，2016年11月3日在新加坡交易所Catalist主板上市，旗下拥有19家诊所，专注于内镜、结直肠及普通外科医疗服务，致力于为新加坡市场提供专业与便捷的医疗服务。
结论
投资者提示：此次对Chirurgia Pte. Ltd.的收购是HC Surgical Specialists Limited的一项战略性举措，预计将提升集团盈利能力，扩展业务版图，为公司未来发展及股价表现带来积极影响。建议股东关注后续整合进展及财务表现公告。
免责声明：本文仅供参考，不构成投资建议。投资者应自行进行尽职调查，并咨询财务顾问后再作投资决策。新交所及公司保荐人未对本文内容进行审核或批准。
